Drug RepurposingPub Date : 1900-01-01DOI: 10.1039/9781839163401-00280
K. V. Phelps
{"title":"Chapter 14. Regulatory Considerations and Strategies for Drug Repositioning","authors":"K. V. Phelps","doi":"10.1039/9781839163401-00280","DOIUrl":"https://doi.org/10.1039/9781839163401-00280","url":null,"abstract":"","PeriodicalId":202024,"journal":{"name":"Drug Repurposing","volume":"43 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121709947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drug RepurposingPub Date : 1900-01-01DOI: 10.1039/9781839163401-00196
A. Reaume, C. Lipinski
{"title":"Chapter 10. Preclinical. A Repurposed Novel Lyn Kinase Activator, MLR-1023, is a Model Example of Pharmacological Pleiotropy","authors":"A. Reaume, C. Lipinski","doi":"10.1039/9781839163401-00196","DOIUrl":"https://doi.org/10.1039/9781839163401-00196","url":null,"abstract":"","PeriodicalId":202024,"journal":{"name":"Drug Repurposing","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131030049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drug RepurposingPub Date : 1900-01-01DOI: 10.1039/9781839163401-00221
Ingmar de Gooijer, R. Brus
{"title":"Chapter 11. Harnessing the Potential of Early Access: Advancing Timely Patient Access to Innovative Medicines in a Sustainable Way","authors":"Ingmar de Gooijer, R. Brus","doi":"10.1039/9781839163401-00221","DOIUrl":"https://doi.org/10.1039/9781839163401-00221","url":null,"abstract":"The way medicines are developed, regulated and priced determines how quickly patients have access to safe, effective and affordable medicines. Patients are increasingly requesting access to investigational medicines and regulators are developing guidelines for additional data collection outside the clinical trial setting. Payors and healthcare policy makers worry about the rising prices of new medicines and are searching for effective policy instruments. Developing effective pharmaceutical policy requires a thorough understanding of the working of the medicine development ecosystem. Currently the smaller players are the drivers of discovery and innovation but are unable to compete in the approved medicine market as they lack the financial capacity to progress to the commercial phase, which limits competition and pricing pressure. Experimenting with innovative funding models for advanced therapy medicinal products, personalized treatments and medicines targeting (progressive) orphan diseases is expected to occur more frequently. One such model that supports smaller medicine developers, and helps them survive transitioning to the commercial stage, is the funding of early access programs. Countries with universal healthcare systems are well suited to experiment with an adaptive funding model for early access that includes pay-for-performance elements based on evolving real-world data and evaluation. Such an approach has the potential to contribute to universal access to new treatments in a sustainable way.","PeriodicalId":202024,"journal":{"name":"Drug Repurposing","volume":"33 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116738467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drug RepurposingPub Date : 1900-01-01DOI: 10.1039/9781839163401-00024
R. Wyse, Antony Cooper, S. Stott
{"title":"Chapter 3. The Role of Clinical Medicine","authors":"R. Wyse, Antony Cooper, S. Stott","doi":"10.1039/9781839163401-00024","DOIUrl":"https://doi.org/10.1039/9781839163401-00024","url":null,"abstract":"","PeriodicalId":202024,"journal":{"name":"Drug Repurposing","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125008179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drug RepurposingPub Date : 1900-01-01DOI: 10.1039/9781839163401-00014
M. Fernandez-Estévez, L. Wrobel, D. Rubinsztein
{"title":"Chapter 2. Role of Academia: Drug Repurposing to Induce Autophagy for Treatment of Neurodegenerative Diseases","authors":"M. Fernandez-Estévez, L. Wrobel, D. Rubinsztein","doi":"10.1039/9781839163401-00014","DOIUrl":"https://doi.org/10.1039/9781839163401-00014","url":null,"abstract":"","PeriodicalId":202024,"journal":{"name":"Drug Repurposing","volume":"148 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116547724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drug RepurposingPub Date : 1900-01-01DOI: 10.1039/9781839163401-00129
S. Avram, R. Curpan, Tudor I. Oprea
{"title":"Chapter 7. Cheminformatics Data Mining and Modeling for Drug Repurposing","authors":"S. Avram, R. Curpan, Tudor I. Oprea","doi":"10.1039/9781839163401-00129","DOIUrl":"https://doi.org/10.1039/9781839163401-00129","url":null,"abstract":"","PeriodicalId":202024,"journal":{"name":"Drug Repurposing","volume":"44 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122654762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drug RepurposingPub Date : 1900-01-01DOI: 10.1039/9781839163401-00101
F. Sheinerman
{"title":"Chapter 6. Screening Technologies","authors":"F. Sheinerman","doi":"10.1039/9781839163401-00101","DOIUrl":"https://doi.org/10.1039/9781839163401-00101","url":null,"abstract":"Screening advanced compounds enables discovery of direct repurposing candidates, novel drug-like leads for optimization, and informative pharmacological probes. In this chapter, we describe different types of screening collections used in drug repurposing, discuss issues and considerations in preparing and executing a repurposing screen, and present examples of in vitro and in vivo repurposing assays. We further describe various data sources reporting information on de-risked compounds of different types and illustrate how data mining and chemoinformatic and chemogenomic searches can be used to access large numbers of advanced compounds and assemble collections most suitable for screening in a given disease model. We argue that a view of repurposing screening as a large-scale bet on finding candidates for clinical testing is narrow and incomplete. Rather, when thoughtfully executed, screening of re-risked compounds is informed by target pathobiology and offers a means to efficiently convert advances in the development of sophisticated non-clinical models and new insights in disease mechanisms into novel drug-like leads and candidates for development.","PeriodicalId":202024,"journal":{"name":"Drug Repurposing","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130454540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}